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MaHyponatremia frequently poses a therapeutic challenge in acute decompensated heart failure (ADHF). Treating physicians
should differentiate between depletional versus dilutional hyponatremia. The former is caused by diuretic agents, which
enhance sodium excretion, often with concomitant potassium/magnesium losses. This can be treated with isotonic saline,
whereas potassium/magnesium administration may be helpful if plasma concentrations are low. In contrast, as impaired
water excretion, rather than sodium deﬁciency, is the culprit in dilutional hyponatremia, isotonic saline administration
may further depress the serum sodium concentration. Because free water excretion is achieved by continuous sodium
reabsorption in distal nephron segments with low water permeability, diuretic agents that impair this mechanism (e.g.,
thiazide-type diuretic agents and mineralocorticoid receptor antagonists) should be avoided, and proximally acting
agents (e.g., acetazolamide and loop diuretic agents) are preferred. Vasopressin antagonists, which promote low water
permeability in the collecting ducts and, hence, free water excretion, remain under investigation for dilutional hypo-
natremia in ADHF. (J Am Coll Cardiol 2015;65:480–92) © 2015 by the American College of Cardiology Foundation.H yponatremia, deﬁned as a serum sodium(Naþ) concentration <135 mEq/l, is themost common electrolyte disorder in hos-
pitalized patients (1). Both admission and hospital-
acquired hyponatremia are associated with an
increased risk for adverse outcomes, including pro-
longed hospital stay, need for discharge to a short-
or long-term care facility, and all-cause mortality
(2). In a subanalysis from the OPTIMIZE-HF (Orga-
nized Program to Initiate Lifesaving Treatment in
Hospitalized Patients with Heart Failure) registry,
including 47,647 patients with acute decompensated
heart failure (ADHF), hyponatremia was present in
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TABLE 1 Pathophysiology of Hyponatremia in
Acute Decompensated Heart Failure
Mechanism of Action
Dilutional hyponatremia
Increased sensitivity of osmotic AVP
release/ Lower osmo-checkpoint*
Baroreceptor activation/angiotensin II
Increased nonosmotic AVP release Baroreceptor activation/angiotensin II
Impaired AVP degradation Liver and/or kidney dysfunction
Increased thirst Baroreceptor activation/angiotensin II
Decreased distal nephron ﬂow Impaired glomerular ﬁltration/Increased
proximal tubular reabsorption
Depletional hyponatremia
Low sodium intake Salt-restricted diet
Exaggerated nonurinary sodium losses Diarrhea, ascites
Exaggerated natriuresis Diuretics, osmotic diuresis
Sodium shift toward the intracellular
compartment
Potassium and/or magnesium
deﬁciency
*This is the level of plasma osmolality that is pursued by the homeostatic mechanisms of the
body.
AVP ¼ arginine vasopressin.
AB BR E V I A T I O N S
AND ACRONYM S
ADHF = acute decompensated
heart failure
AVP = arginine vasopressin
ENaC = epithelial sodium
channel
GFR = glomerular ﬁltration
rate
MRA = mineralocorticoid
receptor antagonist
Naþ = sodium
TAL = thick ascending
limb of Henle’s loop
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481available evidence, a pathophysiology-based assess-
ment and management strategy for the important
clinical challenge of hyponatremia in ADHF.
PATHOPHYSIOLOGY OF
HYPONATREMIA IN ADHF
Table 1 provides a summary of the pathophysiology of
hyponatremia in ADHF.
DILUTIONAL HYPONATREMIA. It is generally assumed
that hyponatremia in ADHF is more often a problem
of impaired water excretion than Naþ depletion (6,7).
Two key events driving increased water retention
and progression of hyponatremia in ADHF are in-
creased nonosmotic release of arginine vasopressin
(AVP) and insufﬁcient tubular ﬂow through diluting
(distal) segments of the nephron. In many ways, this
is the opposite of the situation in diabetes insipidus,
where deﬁcient AVP production and/or function
in the presence of normal tubular ﬂow results in
very diluted urine, exaggerated water losses, and,
ultimately, in hypernatremia, unless compensation
occurs through increased water intake.
AVP and regulat ion of p lasma osmola l i ty . AVP, a
cyclic octapeptide (1,099 D) with a 3-amino acid tail,
is a key regulator of water homeostasis. AVP is syn-
thesized in large-diameter neurons in the supraoptic
and paraventricular nuclei of the anterior hypothal-
amus. After axonal transport into nerve terminals
within the posterior lobe of the pituitary, AVP is
released into the bloodstream in response to plasma
hypertonicity (8). In healthy, normally hydrated
persons, circulating AVP levels are very low
(w1 pg/ml) because of its rapid degradation and
excretion by the liver and kidneys (t1/2 ¼ 15 to 20 min)
(9). Consequently, hepatic dysfunction and renal
insufﬁciency may contribute to increased plasma
levels of AVP in ADHF. AVP exerts its water-retaining
effects primarily through stimulation of high-afﬁnity
V2 receptors in the collecting ducts of the nephron
(Figure 1) (9). V2 stimulation increases both the syn-
thesis and availability of aquaporin-2 channels on the
luminal side of these collecting ducts, which other-
wise have low water permeability (10). The hypertonic
environment of the renal interstitium subsequently
provides a strong impetus for water reabsorption,
resulting in decreased water excretion and, conse-
quently, less diuresis. Importantly, this system is very
sensitive to small changes in plasma AVP levels, which
are difﬁcult to detect, even by modern assays (11). At
higher concentrations, the low-afﬁnity V1a receptor,
which is expressed in the liver, collection ducts,
and vasa recta of the nephron, is stimulated (Figure 1).
This further enhances hypertonicity in the renalinterstitium—hence antidiuresis—through in-
creased hepatic urea production, improved
medullary urea reabsorption in the collecting
ducts, and reduced blood ﬂow through the
vasa recta (Figure 1) (12,13). The vasa recta are
straight capillaries in the renal medulla with a
hairpin loop. They receive a lower proportion
of blood ﬂow compared with the renal cortex,
especially during antidiuresis. This is impor-
tant, as high blood ﬂow through the vasa recta
washes out the tonicity gradient from the
renal cortex toward the medulla, which is
needed to concentrate the urine. Finally,
another effect of V1a receptor stimulation is
promotion of prostaglandin synthesis in the collecting
ducts. This counteracts V2 effects on aquaporin-2, thus
stimulating water excretion (14). This latter effect may
explain why some heart failure patients demonstrate a
normal response to water loading, with production of
adequately diluted urine, despite having elevated
plasma AVP levels (15).
Nonosmot ic arg in ine vasopress in re lease in
heart fa i lure . Several studies have demonstrated
that AVP levels are generally elevated in heart failure
(16–18). Moreover, aquaporin-2 expression was
markedly up-regulated in a rat model of congestive
heart failure (19), which would be expected to in-
crease water permeability and reabsorption in the
collecting ducts of the nephron. It is tempting to
speculate that both events are causally related and
promoting excessive free water reabsorption, leading
to hyponatremia in ADHF. Certainly, baroreceptor
activity, sympathetic overdrive, and angiotensin II,
all stimulated by decreased effective circulatory
FIGURE 1 Effects of AVP in the Nephron
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V2-receptor effects: The primary effect of AVP on water homeostasis is mediated through
stimulation of high-afﬁnity V2 receptors, already with small increases in plasma levels (9).
V2-receptor stimulation in collecting duct cells results in increased production of AP2
channels and facilitates recruitment of these channels on the luminal membrane, which
otherwise has low water permeability (10). Subsequently, water reabsorption is promoted
as the renal interstitium is hypertonic and the basolateral membrane of collecting duct
cells is highly permeable to water. Hypertonicity in the renal interstitium is accomplished
through solute reabsorption in parts of the nephron that have relatively low water
permeability, that is, sodium and chloride transport in the TAL and urea reabsorption in the
medullary part of the collecting ducts through UT-A1 transporters.
V1a-receptor effects: At high plasma levels, AVP further stimulates hypertonicity in the
renal interstitium, and hence water reabsorption, through activation of the low-afﬁnity V1a
receptor. First, this promotes both hepatic urea production and UT-A1 transport in the
medullary part of the collecting ducts, resulting in higher urea concentrations and a
stronger osmotic gradient in the renal interstitium. Furthermore, V1a receptor stimulation
causes vasoconstriction in the vasa recta, preventing wash-out of solutes from the renal
medulla (12,13). On the other hand, V1a receptor stimulation in collecting duct cells also
promotes prostaglandin synthesis. Prostaglandins counteract the effects of V2 by impeding
AP2 recruitment in these collecting duct cells (14). This somewhat preserves the diluting
capacity of the distal nephron, even when AVP levels are high because of neurohumoral
activation and nonosmotic AVP release. AP2 ¼ aquaporin-2; AVP ¼ arginine vasopressin;
TAL ¼ thick ascending limb of Henle’s loop.
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482volume in ADHF, fuel nonosmotic AVP release, as well
as thirst and thus free water intake (20). Importantly,
they also increase the sensitivity of osmotic AVP
release (Figure 2A). Indeed, compared with healthy
volunteers, ADHF patients show a more pronounced
increase in plasma AVP levels with osmotic loading
(21). In contrast to this osmotic AVP release, which
increases linearly and with very small changes in
serum osmolality, nonosmotic AVP release is expo-
nential (Figure 2B). Thus, isotonic plasma volume
reductions of 5% to 10% will have little effect on AVP
secretion, whereas reductions of 20% to 30%,resulting in baroreceptor activation and angiotensin
II stimulation, may cause plasma levels many times
higher than necessary to produce maximal anti-
diuresis (50 to 100 pg/ml) (22). Importantly, at these
high levels, AVP has potent V1a -mediated vasocon-
strictor effects that may contribute to hemodynamic
deterioration in ADHF (23).
Insufﬁcient tubular ﬂow through diluting segments
of the distal nephron. Healthy kidneys are able
to dilute urine to an osmolality as low as 30 to 60
mOsm/l, w5- to 10-fold lower than serum osmolality
(24). However, micropuncture studies have demon-
strated that tubular ﬂuid osmolality is quite similar
(w150 mOsm/l) at the level of the macula densa dur-
ing antidiuresis versus water diuresis (25). Thus,
urine dilution depends heavily on the tubular func-
tion of more distal parts of the nephron (i.e., distal
convoluted tubules and collecting ducts). Free water
excretion is achieved by these segments through
continued solute reabsorption, primarily through the
thiazide-sensitive Naþ/chloride cotransporter and
aldosterone-sensitive epithelial sodium channels
(ENaCs), in the presence of low water permeability
(24,26). Importantly, less sodium is reabsorbed by
ENaCs in conditions of low tubular ﬂow, irrespective
of aldosterone levels (27). Consequently, if more so-
dium is retained in the tubular lumen, free water
excretion is restricted. The ability of the kidneys to
excrete free water is, therefore, directly dependent
on: 1) the amount of tubular ﬂuid offered to the distal
nephron; and 2) the relatively low water permeability
of this segment, which can only be overcome
by insertion of aquaporin-2 channels through AVP
stimulation. For instance, a healthy person with a
glomerular ﬁltration rate (GFR) of 180 l/day
(125 ml/min), of which 10% reaches the distal convo-
luted tubules and with total AVP suppression, would
be able to drinkw18 l (10% of 180 l) over the course of
a day without developing hyponatremia (Figure 3A).
Yet, with the GFR lowered to 43.2 l/day (30 ml/min),
and only 5% distal tubular ﬂow because of increased
proximal reabsorption in ADHF, maximal water
intake without hyponatremia development would
be decreased tremendously to 2.16 l/day (5%
of 43.2 l/day) (28,29). The latter is even an over-
estimate, as it presumes that water permeability in
the distal nephron is as low as with total AVP sup-
pression, which is clearly not the case in ADHF
(Figure 3B). An intriguing study by Bell et al. (30)
further supports the concept of decreased distal
nephron ﬂow in AHDF. In this study, free water
excretion was increased in ADHF patients with
hyponatremia after infusion of 5% mannitol, an os-
motic diuretic that enhances tubular ﬂow through the
FIGURE 2 Determinants of AVP Plasma Levels
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(A) Osmotic AVP release: AVP is near total suppression in normal
circumstances, but increases linearly with plasma osmolality (9).
Neurohumoral activation through angiotensin II and baroreceptor
activity increases the amount of AVP release for any given plasma
osmolality (20). In addition, it moves the set-point of total AVP
suppression to a lower plasma osmolality, hence promoting hy-
potonicity. (B) Osmotic versus nonosmotic AVP release: osmotic
AVP release is very sensitive and increases linearly, already with
very small changes in plasma osmolality (blue curve) (9). Non-
osmotic AVP release makes little contribution to overall AVP
plasma levels until a 10% to 15% decrease in isotonic plasma
volume, after which AVP release increases markedly, resulting in
plasma levels many times higher than needed to achieve maximal
antidiuresis (red curve) (22). Abbreviations as in Figure 1.
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483nephron. Mannitol exerts its diuretic effect through
solvent drag and water retention in the tubular
lumen, thereby also increasing distal delivery. Similar
ﬁndings have been demonstrated in patients with
cirrhosis, where the effective circulatory volume and
renal perfusion are also impaired (31). However, it
remains possible that correction of hyponatremia
with mannitol in ADHF and cirrhosis is partly due to
increased intravascular volume after infusion, sup-
pressing baroreceptor tonus and, hence, nonosmotic
AVP release (32).
DEPLETIONAL HYPONATREMIA. Because increased
Naþ avidity characterizes heart failure from the verybeginning and is exacerbated by unrestrained
neurohumoral up-regulation, Naþ depletion is rela-
tively rare in ADHF not treated with diuretic agents
(33,34). Still, osmotic diuresis because of hypergly-
cemia in the case of severe uncontrolled diabetes,
gastrointestinal losses, and third-space losses may all
contribute to a negative Naþ balance, especially if
patients adhere scrupulously to the salt-restricted
diets recommended by the guidelines (35–37). One
group called these diets into question, demonstrating
that heart failure patients adhering to such diets
experienced increased hospitalizations and a higher
mortality rate (38–40). However, it should be noted
that these patients also received a high dose of
diuretic agents (125 to 500 mg furosemide equivalents
twice daily), increasing the risk of a negative Naþ
balance. Indeed, the combination of very low dietary
sodium intake and exaggerated losses might lead
to progressive depletion of whole-body sodium stores.
Loop diuret i c - induced hyponatremia . The use
of powerful Naþ-wasting loop diuretic agents is
nearly ubiquitous in ADHF, with 88% of patients in
ADHERE (Acute Decompensated Heart Failure Regis-
try) receiving them (41). Moreover, 70% continue to
receive daily maintenance therapy with loop diuretic
agents, although many are probably not persistently
volume-overloaded. Loop diuretic agents block the
Naþ/potassium/chloride cotransporter in the thick
ascending limb of Henle’s loop (TAL). Naþ and chlo-
ride transport in the TAL, which has a relatively low
water permeability, makes a crucial contribution to
the hypertonicity of the renal interstitium, in addition
to the other important factor, medullary urea trans-
port in the collecting ducts (42,43). This hypertonicity,
washed out by blood ﬂow through the vasa recta with
inhibition of TAL transport by loop diuretic agents, is
the major driver of water reabsorption in the distal
nephron. Because of this interference of loop diuretic
agents with the renal capacity to concentrate urine,
less free water is reabsorbed, resulting in production
of hypotonic urine and, therefore, relative protection
against hyponatremia (Figure 4A) (44). However, in
conditions of profound volume depletion with strong
neurohumoral activation and compromised renal
blood ﬂow, loop diuretic agents will fail to elicit
meaningful water diuresis. Eventually, GFR and distal
nephron ﬂow will become depressed in the presence
of strongly up-regulated AVP, creating the necessary
environment for hyponatremia development (29).
Other d iuret i c agents and hyponatremia . Miner-
alocorticoid receptor antagonists (MRAs) are a
cornerstone in the treatment of heart failure with
reduced ejection fraction and are promising in
selected patients with preserved ejection fraction
FIGURE 3 Maximal Free Water Excretion in Healthy Subjects Versus Patients With Heart Failure and an Impaired GFR
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(A) Through glomerular ﬁltration, a healthy person forms 180 l of tubular ﬂuid each day. As the proximal tubules, thin descending limb, and
ascending limb of Henle’s loop all have high water permeability, reabsorption in these nephron segments is isotonic, and tonicity of the tubular
ﬂuid remains at 285 to 295 mOsm/l, equal to plasma. In contrast, the TAL has low water permeability. Thus, solutes in general and sodium/
chloride in particular are reabsorbed without water, contributing to the hypertonicity of the renal interstitium. Consequently, osmolality is
relatively stable (w150 mOsm/l) in the tubular lumen at the level of the macula densa, at which point 90% of reabsorption has occurred, with
10%, or 18 l, remaining on a daily basis (25). In the case of total AVP suppression, the distal nephron has very low water permeability, while
sodium and chloride are continuously reabsorbed; therefore, urine can be diluted up to 30 to 60mOsm/l. Consequently, almost 18 l of free water
excretion can be achieved, which is themaximum a person can drink without developing plasma hypotonicity and hyponatremia. (B)Maximal free
water excretion in a patient with heart failure and a GFR of 30ml/min is considerably lower. In this case, 43.2 l of tubular ﬂuid is formed each day.
As proximal tubular reabsorption increases in heart failure, only 5% or 2.16 l of tubular ﬂuid remains at the level of the macula densa, again with
an osmolality ofw150 mOsm/l (25). As AVP is typically increased in heart failure and the minimal medullar tonicity is greater because of poor
ﬂow through the vasa recta, the osmotic gradient for water reabsorption is increased in the presence of a more leaky distal nephron. Thus, water
is continuously reabsorbed, limiting maximal free water excretion to <1 l. This realistic example illustrates how difﬁcult it can be for a patient to
prevent hyponatremia progression with ﬂuid restriction only. GFR ¼ glomerular ﬁltration rate; other abbreviations as in Figure 1.
Verbrugge et al. J A C C V O L . 6 5 , N O . 5 , 2 0 1 5
Hyponatremia in Decompensated Heart Failure F E B R U A R Y 1 0 , 2 0 1 5 : 4 8 0 – 9 2
484
FIGURE 4 Effects of Diuretics on the Kidney’s Concentrating and Diluting Capacity
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(A) Loop diuretic agents block the sodium/chloride/potassium cotransporter in the TAL, interfering with the generation of hypertonicity in the
renal interstitium and decreasing the osmotic gradient that promotes water reabsorption. Loop diuretic agents have no effect on sodium or
chloride transport in the distal nephron, which has low water permeability, and they therefore do not interfere with the kidneys’ capacity to
produce hypotonic urine. (B) Thiazide-type diuretic agents block the sodium/chloride symporter, whereas MRAs inhibit ENaCs in the distal
nephron. As both make a negligible contribution to the hypertonicity achieved in the renal interstitium, thiazide-type diuretic agents and MRAs
do not interfere with the water reabsorption gradient. However, as sodium and chloride reabsorption in the relatively water-impermeable distal
nephron is the mechanism of urinary dilution, this process is impaired, resulting in a higher urinary tonicity and, hence, lower free water
excretion compared with loop diuretic agents. ENaC ¼ epithelial sodium channel; MRA ¼ mineralocorticoid receptor antagonists; other
abbreviations as in Figure 1.
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486(45,46). Together with thiazide-type diuretic agents,
often recommended as ﬁrst-line therapy in case of
loop diuretic resistance, they interfere with sodium
reabsorption by ENaCs and Naþ/chloride cotrans-
porters, respectively, in the distal convoluted tubules
and collecting ducts (Figure 4B) (47). Thus, they
have a direct effect on the diluting tubular segments
of the kidneys and may cause hyponatremia, even
without pronounced hypovolemia, as they generate
less hypotonic urine (47–49). From a pathophysio-
logical perspective, it is, therefore, prudent to
avoid their use in any patient with hyponatremia—at
least temporarily, until serum sodium levels are
corrected—and to prefer a proximally working
diuretic (e.g., acetazolamide) in such cases with vol-
ume overload and diuretic resistance (29).
Potass ium and magnes ium deplet ion . Both loop-
and thiazide-type diuretic agents are a major cause of
potassium andmagnesiumwasting in ADHF. This may
have important implications, such as a higher risk of
arrhythmic death (50). In addition, potassium deple-
tion shifts Naþ towards the intracellular compartment
to preserve cellular volume homeostasis, which may
contribute to development of hyponatremia (51).
Indeed, intracellular Naþ concentrations are higher in
muscle cells of ADHF patients with hypokalemia (52).
Furthermore, magnesium is critical for functioning of
the Naþ/potassium ATPase that pumps Naþ out of
cells; thus, hypomagnesemia may also exacerbate
extracellular Naþ depletion.
INITIAL APPROACH TO HYPONATREMIA IN
DECOMPENSATED HEART FAILURE
The Central Illustration presents a stepwise diagnostic
and therapeutic approach to hyponatremia in de-
compensated heart failure.
CONFIRM PLASMA HYPOTONICITY. In patients with
hyponatremia, the ﬁrst step is generally to assess
whether plasma hypotonicity is present by measuring
the plasma osmolality (reference value: 285 to
295 mOsm/l). This may not be necessary when
hyponatremia is mild (serum Naþ concentration
130 to 134 mEq), asymptomatic, and easily corrected
by empiric treatment. Elevated triglyceride or
cholesterol levels, immunoglobulins, and monoclonal
gammopathies—through laboratory artifacts—may all
cause falsely low serum Naþ concentrations without
affecting plasma osmolality (53–55). Additionally,
the presence of effective osmoles raising serum
osmolality—most notably glucose in uncontrolled
diabetes and/or hyperosmolar radiocontrast media—
may result in hyponatremia with normal, or even
high, plasma tonicity (56,57). Indeed, the serum Naþconcentration decreases by approximately 2.4 mEq/l
per 100 mg/dl increase in serum glucose (56). If these
underlying causes are managed appropriately, hypo-
natremia is probably not associated with worse
outcome (58).
AVOID AND TREAT DEPLETIONAL HYPONATREMIA.
In any patient with hypotonic hyponatremia, it is best
to avoid thiazide-type diuretic agents, MRAs, and
ENaC blockers (e.g., amiloride), as these medications
interfere directly with the kidneys’ capacity to pro-
duce hypotonic urine. However, it should be stressed
that this advice is purely on the basis of the patho-
physiological rationale, as high-quality evidence is
lacking. Further, potassium and magnesium stores
should be replenished if serum levels are low. We
propose aiming for serum potassium levels $4 mEq/l
and magnesium levels $1.7 mEq/l ($2 mg/dl) in ADHF
patients presenting with hyponatremia, but this cut-
off is arguably somewhat arbitrary.
DIFFERENTIATE BETWEEN DEPLETIONAL AND
DILUTIONAL HYPONATREMIA. In ADHF, clinicians
should differentiate between depletional hypo-
natremia, requiring the administration of saline,
versus dilutional hyponatremia, where free water
excretion should be promoted. Acute gastrointestinal
or third-space losses, clinical signs of hypovolemia,
and recent use of diuretic agents—especially at high
doses or in combination therapy—increase the likeli-
hood of depletional hyponatremia. In this case, pro-
duction of hypotonic urine is promoted by the
administration of isotonic saline, with subsequent
normalization of serum sodium levels. In contrast, it
would be impossible to correct dilutional hypona-
tremia with isotonic saline, as free water excretion is
compromised and hypotonic urine production is
impaired. One might consider a ﬂuid challenge with 1
of isotonic saline over 24 h to differentiate between
these conditions, measuring the effect on serum so-
dium levels. However, this should be avoided in case
of clear ﬂuid overload and/or severe hyponatremia
(serum sodium <125 mEq/l). Indeed, signs of volume
overload indicate a component of dilutional hypona-
tremia, in which case an improvement is unlikely,
and the risk of further deteriorating congestion is
substantial. Further worsening of hyponatremia
should certainly be avoided in patients with severe
hyponatremia. Alternatively, one could measure
urine osmolality, which should be adequately sup-
pressed (<100 mOsm/l) in patients with depletional
hyponatremia, but not in patients with dilutional
hyponatremia. If urine osmolality is >150 mOsm/l,
isotonic solutions should certainly be avoided, as
administration would result in further worsening of
CENTRAL ILLUSTRATION Approach to Hyponatremia in Decompensated Heart Failure
Assess plasma osmolality (can be skipped in cases of mild hyponatremia that is easily corrected with initiation of therapy)
Differentiate between 
hyponatremia conditions Water Excess (dilutional)Na
+ deficit (depletional)
Pseudohyponatremia
(Plasma osmolality ≥285 mOsm/L)
Falsely low serum Na+ concentrations caused by laboratory artefacts (elevated 
triglyceride/cholesterol levels, immunoglobulins and monoclonal gammopathies)
Increased plasma osmolality caused by hyperglycemia, hyperosmolar 
radio-contrast media, use of mannitol, ethanol, methanol, ethylene glycol
Hypotonic hyponatremia
(Plasma osmolality <285 mOsm/L)
Depletional hyponatremia
• Negative Na+ balance
• Potassium (K+) and magnesium (Mg++) depletion
Clinical presentation:
• Hypovolemia
Caused by:
• Use of powerful Na+-wasting loop diuretics
• Use of thiazide-type or combinational diuretics
• Salt-restricted diets recommended by the guidelines
• Acute gastro-intestinal or third-space losses
Urinary analysis:
• Urinary osmolality adequately suppressed (<100 mOsm/L)
• Urinary sodium depleted (<50 mEq/L) 
Dilutional hyponatremia
• Impaired water excretion
• Excessive water reabsorption
Clinical presentation:
• Hypervolemia (Edema, ascites, pleural effusion)
Caused by:
• Non-osmotic release of arginine vasopressin (AVP)
• Insufficient tubular flow through diluting segments
of the distal nephron
Urinary analysis:
• Urinary osmolality inadequately suppressed (≥100 mOsm/L) 
Depletional hyponatremia
• Administer saline. One liter of infusate is expected
to change the serum sodium concentration with:
Dilutional hyponatremia
• Limit water intake
• Promote free water excretion
- AVP
- Improve distal nephron flow (loop diuretics with
or without hypertonic saline, acetazolamide, 
renin-angiotensin system blockers, inotropes
and vasodilator therapy)
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Hyponatremia: Serum sodium (Na+) ≤135 mEq/L
For both depletional and dilutional hyponatremia
• Stop distally working diuretics (thiazide-type, amiloride, mineralocorticoid receptor antagonists)
• Correction of K+ and Mg++ deficiencies (aiming for serum K+ levels ≥4 mEq/L and Mg++ levels ≥1.7 mEq/L)
DI
AG
NO
SI
S
DE
FI
NI
TI
ON
(Na+)infusate + (K+)infusate – (Na+)serum
(TBW + 1)
TBW = α x body weight (kg); α = 0.6 in children and non-elderly men,
0.5 in non-elderly women and elderly men, 0.45 in elderly women
Verbrugge, F.H. et al. J Am Coll Cardiol. 2015; 65(5):480–92.
A ﬂowchart with a stepwise diagnostic approach to hyponatremia in decompensated heart failure is presented. Therapeutic options are
proposed according to the underlying pathophysiological culprit. AVP ¼ arginine vasopressin.
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488hyponatremia. Finally, very low urinary Naþ and/or
chloride concentrations (<50 mEq/l) are a relatively
strong argument for electrolyte depletion.
TREATMENT OF DEPLETIONAL
HYPONATREMIA
As with other deﬁciencies, pure depletional hypo-
natremia is easily treated by administration of saline.
Hypertonic saline will correct hyponatremia faster and
with a lower water load than isotonic saline, which
might be preferred in patients who are already nor-
movolemic on clinical examination. However, if no
severe hyponatremia symptoms are present, it is rec-
ommended to correct the serum Naþ concentration
slowly, at a maximal rate of 5 mEq/l per day. If hypo-
natremia is profound (<125 mEq/l), correction up to
10 mEq/l per day is acceptable (59). At any time,
increasing the serum Naþ concentration >10 mEq/l in
24 h should be avoided because of the risk of central
pontinemyelinolysis (60). Importantly, replenishment
of potassium and magnesium stores through adminis-
tration of supplements contributes to hyponatremia
correction, and this should be taken into account when
determining the correction rate (52,61). Although
certainly not a substitute for frequent monitoring, the
change in serum Naþ concentration with 1 l of infusate
might be approximated by the following formula:

Naþ

INFUSATE þ

Kþ

INFUSATE 

Naþ

SERUM
 ðTBW þ 1Þ
with TBW ¼ a  body weight (kg), and a ¼ 0.6 in chil-
dren and nonelderly men, 0.5 in nonelderly women
and elderly men, and 0.45 in elderly women (62). Take
for example a female patient, 50 years of age and
weighing 62 kg, presents with a serum Naþ concen-
tration of 130mEq/l and a serumKþof 3.5mEq/l. This is
presumably because of depletion, as she is on a high
maintenance dose of furosemide (120 mg twice daily)
and has no overt signs of volume overload. Infusion of
1 normal saline ([Naþ] ¼ 154 mEq/l) with addition of
40 mEq Kþ supplements would be expected to raise
the serum Naþ concentration by 2 mEq/l ([154 mEq/l þ
40 mEq/l  130 mEq/l]/[(0.5  62) þ 1]). However,
without Kþ supplements, the increase would only be
0.75 mEq/l ([154 mEq/l  130 mEq/l]/[(0.5  62) þ 1]).
TREATMENT OF HYPOTONIC
DILUTIONAL HYPONATREMIA
Acute treatment of hypotonic dilutional hypo-
natremia is focused on promoting free water excretion
to restore normal serum sodium levels. However, for
long-term treatment success, it is important to subse-
quently prevent a positive free water balance. Thismay be important, as the question whether hypona-
tremia in ADHF reﬂects a therapeutic target or is
merely a marker of advanced disease has not been
fully established. Indeed, studies looking at the
prognostic effect of hyponatremia correction have
yielded conﬂicting results (63,64). Madan et al. (63)
demonstrated in a cohort of 322 ADHF patients with
hyponatremia that long-term changes in serum Naþ
concentration (assessed 60 to 270 days after hospital
discharge) are signiﬁcant predictors of mortality, with
improving hyponatremia associated with better
outcome. In contrast, after correction for disease
severity markers, Lee et al. (64) found that normali-
zation of hyponatremia at hospital discharge was not
associated with improved survival (64). Obviously,
confounding by different treatment strategies in both
studies cannot be excluded, but a conservative
interpretation is that only durable hyponatremia
correction is potentially associated with improved
outcome in ADHF. To achieve this, good heart failure
management is often fundamental.
ACUTE TREATMENT OF DILUTIONAL HYPONATREMIA.
To promote free water excretion in a patient with
ADHF and hypotonic dilutional hyponatremia, distal
nephron ﬂow should be increased, AVP levels should
be lowered, or AVP effects should be antagonized.
Loop diuret i c agents with or without hypertonic
sa l ine . The powerful inhibitory effect of loop
diuretic agents on Naþ transport in the TAL increases
the amount of tubular ﬂuid presented to the distal
nephron. Loop diuretic agents also reduce hyperto-
nicity of the renal interstitium, further facilitating
water excretion (Figure 4A) (44). Because loop
diuretic agents are cheap and readily available, they
remain the ﬁrst-line therapy in ADHF with dilutional
hyponatremia and volume overload. The addition of
hypertonic saline to improve loop diuretic efﬁcacy in
ADHF is a controversial issue. Although counterin-
tuitive from a pathophysiological point of view, some
small studies have suggested more efﬁcient decon-
gestion and better renal preservation when loop
diuretic agents are combined with hypertonic saline
(Table 2) (65–70). Importantly, decreases in plasma
renin activity, inﬂammatory markers, and even
natriuretic peptide levels have been demonstrated
with hypertonic saline administration in ADHF
patients who receive loop diuretic agents (71,72). Still,
it remains difﬁcult to draw any ﬁrm conclusions,
because the use of high doses of loop diuretic agents
that might have induced these alterations might
have confounded these improvements with sodium
loading. As serum Naþ levels are more easily cor-
rected, patients with hyponatremia might beneﬁt
more from the addition of hypertonic saline to loop
TABLE 2 Studies on Hypertonic Saline in Patients With Acute Decompensated
Heart Failure
First Author (Ref. #) n Treatment Outcome
Paterna et al. (65) 60 IV furosemide 500–1,000 mg
with vs. without 150 ml
1.4%–4.6% hypertonic
saline BID
Increase in diuresis, natriuresis,
and serum sodium levels;
decrease in serum creatinine;
and shorter hospitalization
time with hypertonic saline
Licata et al. (66) 107 IV furosemide 500–1,000 mg
with vs. without 150 ml
1.4%–4.6% hypertonic
saline BID
Increase in diuresis, natriuresis,
and serum sodium levels;
decrease in serum creatinine;
and improved survival with
hypertonic saline
Paterna et al. (71) 94 IV furosemide 500–1,000 mg
with vs. without 150 ml
1.4%–4.6% hypertonic
saline BID
Increase in diuresis and
natriuresis; decrease in BNP
levels; shorter hospitalization
time; and lower 30-day
readmission rate with
hypertonic saline
Parrinello et al. (67) 133 IV furosemide 250 mg plus
150 ml 3% hypertonic
saline BID vs. IV furosemide
250 mg BID plus low
sodium diet (<80 mmol)
Increase in diuresis, natriuresis,
and serum sodium levels;
improved renal function; and
faster reduction of echo-
PCWP with hypertonic saline
Paterna et al. (68) 1,771 IV furosemide 250 mg plus
150 ml 3% hypertonic
saline BID vs. IV furosemide
250 mg BID plus low
sodium diet (<80 mmol)
Increase in diuresis, natriuresis,
and serum sodium levels;
decrease in serum creatinine;
shorter hospitalization time;
lower readmission rate; and
improved survival with
hypertonic saline
Issa et al. (69) 34 100 ml 7.5% hypertonic saline
BID vs. placebo for 3 days
Improved in glomerular and
tubular biomarkers with
hypertonic saline
Okuhara et al. (70) 44 500 ml 1.7% hypertonic saline
vs. glucose 5% with 40 mg
furosemide
Improved GFR and better diuresis
with hypertonic saline
BID ¼ twice daily; BNP ¼ B-type natriuretic peptide; GFR ¼ glomerular ﬁltration rate; IV ¼ intravenous;
PCWP ¼ pulmonary capillary wedge pressure.
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speculative.
Acetazolamide . Alternatively, combinational diu-
retic treatment with loop diuretic agents and acet-
azolamide ensures minimal tubular Naþ reabsorption
proximal from the macula densa and maximal ﬂow
through the distal nephron (29). For this reason, if
combination therapy is needed to overcome loop
diuretic resistance in ADHF, acetazolamide should be
preferred over thiazide-type diuretic agents, MRAs, or
ENaC blockers.
AVP antagon is ts . AVP antagonists are the only
medication class to directly promote free water
excretion by prevention of aquaporin-2 channel
availability in the collecting ducts of the nephron
(73,74). Three oral V2 receptor antagonists (tolvaptan,
satavaptan, and lixivaptan) have been tested for
ADHF, with the former 2 shown to be efﬁcacious in
restoring serum Naþ levels in patients with volume
overload and hyponatremia (75–78). Similar data are
available for conivaptan, an intravenous agent that
antagonizes both the V2 and V1a receptors (74,79,80).
Table 3 summarizes the currently available evidence
on AVP antagonists in patients with ADHF and hypo-
natremia. Importantly, EVEREST (Efﬁcacy of Vaso-
pressin Antagonism in Heart Failure Outcome Study
with Tolvaptan), including 4,133 patients with ADHF
but without hyponatremia as an inclusion criterion,
compared tolvaptan with placebo and was powered
for clinical endpoint analysis (81). The overall trial did
not show a signiﬁcant reduction in all-cause mortality
or readmission rates, but, interestingly, a subanalysis
in patients presenting with pronounced hypona-
tremia (<130 mmol/l) suggested improved survival
free from cardiovascular death or readmission (76,81).
This promising ﬁnding warrants further study in an
adequately powered, randomized clinical trial.
LONG-TERM MANAGEMENT OF HYPOTONIC DILU-
TIONAL HYPONATREMIA. Water rest r i c t ion . Water
restriction is uniformly recommended by the guide-
lines in ADHF patients with hyponatremia as it is in
others with dilutional hypotonic hyponatremia (35–
37,59). Whilst limiting free water intake certainly
aids to prevent a positive free water balance, few data
support its long-term efﬁcacy, and adherence might
be a problem. Indeed, thirst is a frequent, under-
recognized, and distressing problem in heart failure,
and many patients may ﬁnd it difﬁcult to comply with
strict water restriction (<1 l) (82). Nevertheless, a
recent study found that ADHF patients with mild
hyponatremia had improvements in quality of life
with such a strategy (83).
AVP antagonists . Although AVP antagonists are
highly efﬁcacious for short-term correction ofhyponatremia, less is known about their long-term
efﬁcacy in providing a sustained correction of serum
Naþ levels. In EVEREST, serum Naþ concentration
increased more with tolvaptan compared with pla-
cebo during in-hospital stay (81). However, patients
also reported feeling thirsty signiﬁcantly more
frequently, and the difference with serum Naþ levels
in the placebo group disappeared after instillation of
outpatient management, which suggests that patients
may have drank more to compensate for increased
water losses.
Renin-angiotensin system blockers. Renin-angiotensin
system blockers are known to increase renal blood
ﬂow and decrease proximal tubular sodium reab-
sorption. Therefore, it is not surprising that they were
among the ﬁrst agents demonstrated to be effective in
hypotonic dilutional hyponatremia in heart failure
(84,85). Up-titration of renin-angiotensin system
blockers should always be promoted for this indica-
tion if there are no contraindications, such as coex-
isting renal dysfunction.
TABLE 3 Studies on AVP Antagonists in Patients With Acute Decompensated Heart
Failure and Hyponatremia
First Author (Ref. #) n/N Treatment Outcome
Gheorghiade et al. (77) 71/254
(subgroup
analysis)
Tolvaptan 30, 45, or
60 mg vs. placebo
Normalization of serum
sodium after 24 h,
greater decrease in body
weight and edema,
increased urine output
with tolvaptan
Gheorghiade et al. (78) 51/319
(subgroup
analysis)
Tolvaptan 30, 60, or
90 mg vs. placebo
Normalization of serum
sodium with tolvaptan
Ghali et al. (79) 19/74
(subgroup
analysis)
Conivaptan 40 or
80 mg vs. placebo
Normalization of serum
sodium with conivaptan
Zeltser et al. (80) 28/84
(subgroup
analysis)
Conivaptan 40 or
80 mg vs. placebo
Increase in serum sodium
concentration with
conivaptan
Konstam et al. (81) 1,157/4,133
(subgroup
analysis)
Tolvaptan 30 mg vs.
placebo
No effect on mortality or
rehospitalization,
signiﬁcant increase in
serum sodium with
tolvaptan
Aronson et al. (75) 90/118
(subgroup
analysis)
Satavaptan 25 or 50 mg
vs. placebo
Increase in serum sodium
concentration with
satavaptan
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490Inotropes and vasodi la tor therapy . Increasing the
effective circulatory volume in heart failure is ex-
pected to result in less nonosmotic AVP release
and better renal blood ﬂow, which, from a patho-
physiological perspective, might help to correct dilu-
tional hyponatremia. Because cardiac output in ADHF
is rather insensitive to changes in cardiac pre-load—as
the Frank-Starling mechanism is depleted—improve-
ments can only be obtained through direct stimula-
tion of contractility with inotropes or reducing
afterload with vasodilator therapy. As the former
treatment strategy is associated with increasedmortality, afterload reduction probably remains the
best option to increase the effective circulatory vol-
ume; however, its use is limited by low arterial blood
pressure (86,87). Observational data have demon-
strated that nitroprusside, titrated on arterial blood
pressure and with conversion to oral hydralazine and
nitrates, is feasible and potentially associated with
better outcomes in ADHF (88,89). Alternatively, ser-
elaxin, a vasodilator agent under investigation, might
be of particular interest because of its speciﬁc renal
vasodilator properties (90,91). The RELAX-AHF-EU
(Effect of Serelaxin Versus Standard of Care in Acute
Heart Failure Patients) trial is currently enrolling
ADHF patients and is powered for clinical endpoint
evaluation (92). Nevertheless, the speciﬁc effects of
both inotropes and vasodilator therapy on hypo-
natremia remain insufﬁciently elucidated.
CONCLUSIONS
The pathophysiology of hyponatremia in ADHF is
complex, and a 1-size-ﬁts-all approach is therefore
likely to fail. Appropriate differentiation between
dilutional and depletional hyponatremia is crucial
and depends on good history taking, clinical exami-
nation, and correct interpretation of laboratory re-
sults. A targeted, pathophysiology-based approach
should help to treat this challenging condition efﬁ-
ciently, thereby minimizing adverse events.
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